Cargando…

Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer

INTRODUCTION: As high cholesterol level has been reported to be associated with cancer cell growth and cholesterol is vulnerable to oxidation, the conventional liposomes including cholesterol in the formulation seem to be challenged. Timosaponin AIII (TAIII), as a steroid saponin from Anemarrhena as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lijuan, Zhang, Shengan, Jiang, Min, Lu, Lu, Ding, Yue, Ma, Ninghui, Zhao, Yuan, Xuchen, Sihan, Zhang, Nailian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379713/
https://www.ncbi.nlm.nih.gov/pubmed/34429598
http://dx.doi.org/10.2147/IJN.S313759
_version_ 1783741064539013120
author Zhang, Lijuan
Zhang, Shengan
Jiang, Min
Lu, Lu
Ding, Yue
Ma, Ninghui
Zhao, Yuan
Xuchen, Sihan
Zhang, Nailian
author_facet Zhang, Lijuan
Zhang, Shengan
Jiang, Min
Lu, Lu
Ding, Yue
Ma, Ninghui
Zhao, Yuan
Xuchen, Sihan
Zhang, Nailian
author_sort Zhang, Lijuan
collection PubMed
description INTRODUCTION: As high cholesterol level has been reported to be associated with cancer cell growth and cholesterol is vulnerable to oxidation, the conventional liposomes including cholesterol in the formulation seem to be challenged. Timosaponin AIII (TAIII), as a steroid saponin from Anemarrhena asphodeloides Bunge, possesses a similar structure with cholesterol and exhibits a wide range of antitumor activities, making it possible to develop a TAIII-based liposome where TAIII could potentially stabilize the phospholipid bilayer as a substitution of cholesterol and work as a chemotherapeutic drug as well. Meanwhile, TAIII could enhance the uptake of doxorubicin hydrochloride (DOX) in human hepatocellular carcinoma (HCC) cells and exhibit synergistic effect. Thus, we designed a novel thermally sensitive multifunctional liposomal system composed of TAIII and lipids to deliver DOX for enhanced HCC treatment. METHODS: The synergistic effects of DOX and TAIII were explored on HCC cells and the tumor inhibition rate of TAIII-based liposomes carrying DOX was evaluated on both subcutaneous and orthotopic transplantation tumor models. TAIII-based multifunctional liposomes were characterized. RESULTS: Synergistic HCC cytotoxicity was achieved at molar ratios of 1:1, 1:2 and 1:4 of DOX/TAIII. TAIII-based liposomes carrying a low DOX dose of 2 mg/kg exhibited significantly enhanced antitumor activity than 5 mg/kg of DOX without detected cardiotoxicity on both subcutaneous and orthotopic transplantation tumor models. TAIII-based liposomes were characterized with smaller size than cholesterol liposomes but exhibited favorable stability. Mild hyperthermia generated by laser irradiation accelerated the release of DOX and TAIII from liposomes at tumor site, and cell permeability of TAIII enhanced uptake of DOX in HCC cells. CONCLUSION: The innovative application of TAIII working as bilayer stabilizer and chemotherapeutic drug affords a stable multifunctional liposomal delivery system for synergistic therapy against HCC, which may be referred for the development of other types of saponins with similar property.
format Online
Article
Text
id pubmed-8379713
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83797132021-08-23 Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer Zhang, Lijuan Zhang, Shengan Jiang, Min Lu, Lu Ding, Yue Ma, Ninghui Zhao, Yuan Xuchen, Sihan Zhang, Nailian Int J Nanomedicine Original Research INTRODUCTION: As high cholesterol level has been reported to be associated with cancer cell growth and cholesterol is vulnerable to oxidation, the conventional liposomes including cholesterol in the formulation seem to be challenged. Timosaponin AIII (TAIII), as a steroid saponin from Anemarrhena asphodeloides Bunge, possesses a similar structure with cholesterol and exhibits a wide range of antitumor activities, making it possible to develop a TAIII-based liposome where TAIII could potentially stabilize the phospholipid bilayer as a substitution of cholesterol and work as a chemotherapeutic drug as well. Meanwhile, TAIII could enhance the uptake of doxorubicin hydrochloride (DOX) in human hepatocellular carcinoma (HCC) cells and exhibit synergistic effect. Thus, we designed a novel thermally sensitive multifunctional liposomal system composed of TAIII and lipids to deliver DOX for enhanced HCC treatment. METHODS: The synergistic effects of DOX and TAIII were explored on HCC cells and the tumor inhibition rate of TAIII-based liposomes carrying DOX was evaluated on both subcutaneous and orthotopic transplantation tumor models. TAIII-based multifunctional liposomes were characterized. RESULTS: Synergistic HCC cytotoxicity was achieved at molar ratios of 1:1, 1:2 and 1:4 of DOX/TAIII. TAIII-based liposomes carrying a low DOX dose of 2 mg/kg exhibited significantly enhanced antitumor activity than 5 mg/kg of DOX without detected cardiotoxicity on both subcutaneous and orthotopic transplantation tumor models. TAIII-based liposomes were characterized with smaller size than cholesterol liposomes but exhibited favorable stability. Mild hyperthermia generated by laser irradiation accelerated the release of DOX and TAIII from liposomes at tumor site, and cell permeability of TAIII enhanced uptake of DOX in HCC cells. CONCLUSION: The innovative application of TAIII working as bilayer stabilizer and chemotherapeutic drug affords a stable multifunctional liposomal delivery system for synergistic therapy against HCC, which may be referred for the development of other types of saponins with similar property. Dove 2021-08-16 /pmc/articles/PMC8379713/ /pubmed/34429598 http://dx.doi.org/10.2147/IJN.S313759 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Lijuan
Zhang, Shengan
Jiang, Min
Lu, Lu
Ding, Yue
Ma, Ninghui
Zhao, Yuan
Xuchen, Sihan
Zhang, Nailian
Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title_full Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title_fullStr Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title_full_unstemmed Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title_short Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
title_sort novel timosaponin aiii-based multifunctional liposomal delivery system for synergistic therapy against hepatocellular carcinoma cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379713/
https://www.ncbi.nlm.nih.gov/pubmed/34429598
http://dx.doi.org/10.2147/IJN.S313759
work_keys_str_mv AT zhanglijuan noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT zhangshengan noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT jiangmin noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT lulu noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT dingyue noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT maninghui noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT zhaoyuan noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT xuchensihan noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer
AT zhangnailian noveltimosaponinaiiibasedmultifunctionalliposomaldeliverysystemforsynergistictherapyagainsthepatocellularcarcinomacancer